Yakira Capital Management Inc. Has $2.82 Million Stock Holdings in Surmodics, Inc. (NASDAQ:SRDX)

Yakira Capital Management Inc. grew its stake in Surmodics, Inc. (NASDAQ:SRDX - Free Report) by 103.2% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 71,113 shares of the company's stock after acquiring an additional 36,113 shares during the quarter. Yakira Capital Management Inc. owned 0.50% of Surmodics worth $2,816,000 at the end of the most recent quarter.

Several other hedge funds also recently bought and sold shares of SRDX. Oddo BHF Asset Management Sas acquired a new stake in Surmodics during the 3rd quarter worth $6,593,000. Boussard & Gavaudan Investment Management LLP bought a new position in shares of Surmodics during the 4th quarter valued at about $3,899,000. DLD Asset Management LP bought a new position in shares of Surmodics during the 4th quarter valued at about $2,514,000. State Street Corp grew its position in shares of Surmodics by 19.2% in the 3rd quarter. State Street Corp now owns 374,068 shares of the company's stock valued at $14,506,000 after purchasing an additional 60,240 shares during the period. Finally, Gardner Lewis Asset Management L P increased its stake in Surmodics by 23.5% during the 4th quarter. Gardner Lewis Asset Management L P now owns 262,878 shares of the company's stock worth $10,410,000 after purchasing an additional 49,944 shares in the last quarter. 96.63% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

SRDX has been the topic of a number of research reports. Needham & Company LLC reaffirmed a "hold" rating on shares of Surmodics in a research note on Thursday, January 30th. StockNews.com began coverage on shares of Surmodics in a research report on Monday, February 3rd. They issued a "hold" rating on the stock. Finally, Lake Street Capital upgraded Surmodics from a "hold" rating to a "buy" rating and set a $43.00 target price for the company in a report on Friday, March 7th. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average target price of $50.00.

Surmodics Stock Up 3.0 %

Shares of NASDAQ SRDX traded up $0.81 during midday trading on Friday, reaching $28.05. The company's stock had a trading volume of 14,852 shares, compared to its average volume of 279,639. Surmodics, Inc. has a fifty-two week low of $25.17 and a fifty-two week high of $42.44. The stock has a 50 day simple moving average of $31.24 and a 200-day simple moving average of $35.98. The stock has a market capitalization of $400.93 million, a price-to-earnings ratio of -27.76 and a beta of 1.30. The company has a current ratio of 5.45, a quick ratio of 4.29 and a debt-to-equity ratio of 0.26.

Surmodics (NASDAQ:SRDX - Get Free Report) last issued its quarterly earnings results on Thursday, February 6th. The company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.04. Surmodics had a negative net margin of 11.48% and a negative return on equity of 4.39%. Equities research analysts predict that Surmodics, Inc. will post 0.2 earnings per share for the current year.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).